BNP Paribas Arbitrage SA Has $537,000 Holdings in bluebird bio, Inc. (BLUE)
BNP Paribas Arbitrage SA raised its position in bluebird bio, Inc. (NASDAQ:BLUE) by 514.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,114 shares of the biotechnology company’s stock after buying an additional 4,282 shares during the period. BNP Paribas Arbitrage SA’s holdings in bluebird bio were worth $537,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. FMR LLC boosted its position in bluebird bio by 0.6% in the 1st quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock valued at $556,918,000 after buying an additional 37,742 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in bluebird bio in the 1st quarter valued at about $858,000. Winfield Associates Inc. boosted its position in bluebird bio by 6.1% in the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after buying an additional 162 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in bluebird bio in the 2nd quarter valued at about $3,257,000. Finally, Alliancebernstein L.P. boosted its position in bluebird bio by 50.1% in the 1st quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock valued at $7,805,000 after buying an additional 28,640 shares during the last quarter.
In other news, Director Daniel Lynch sold 2,500 shares of bluebird bio stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $120.03, for a total transaction of $300,075.00. Following the sale, the director now directly owns 5,300 shares in the company, valued at approximately $636,159. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Philip D. Gregory sold 2,250 shares of bluebird bio stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $103.83, for a total transaction of $233,617.50. Following the sale, the insider now owns 33,734 shares in the company, valued at $3,502,601.22. The disclosure for this sale can be found here. Insiders sold a total of 147,248 shares of company stock worth $16,947,505 over the last 90 days. Company insiders own 3.90% of the company’s stock.
Shares of bluebird bio, Inc. (NASDAQ:BLUE) opened at 126.30 on Thursday. bluebird bio, Inc. has a 1-year low of $37.05 and a 1-year high of $133.10. The company’s 50-day moving average is $103.57 and its 200 day moving average is $95.55. The firm’s market cap is $5.76 billion.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.66) by ($0.07). The company had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.59) earnings per share. On average, equities research analysts expect that bluebird bio, Inc. will post ($6.84) EPS for the current fiscal year.
A number of research firms have weighed in on BLUE. BTIG Research reissued a “buy” rating and issued a $112.00 price objective on shares of bluebird bio in a research report on Thursday, June 1st. Zacks Investment Research cut shares of bluebird bio from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub cut shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $88.00 price objective on shares of bluebird bio in a research report on Friday, August 11th. Finally, Maxim Group raised shares of bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $107.86.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.